BR112016010025A2 - molécula de ligação de antígeno contendo região variável de anticorpo modificado - Google Patents
molécula de ligação de antígeno contendo região variável de anticorpo modificadoInfo
- Publication number
- BR112016010025A2 BR112016010025A2 BR112016010025A BR112016010025A BR112016010025A2 BR 112016010025 A2 BR112016010025 A2 BR 112016010025A2 BR 112016010025 A BR112016010025 A BR 112016010025A BR 112016010025 A BR112016010025 A BR 112016010025A BR 112016010025 A2 BR112016010025 A2 BR 112016010025A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen binding
- binding molecule
- variable region
- antibody variable
- molecule containing
- Prior art date
Links
- 230000027455 binding Effects 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Abstract
os presentes inventores referem-se com sucesso a uma molécula de ligação de antígeno compreendendo uma região variável de um anticorpo que tenha atividade de ligação contra a molécula expressa na superfície de uma célula t e uma molécula expressa na superfície de qualquer outro imunócito, mas não se ligue a essas moléculas ao mesmo tempo. a presente invenção refere-se à preparação de uma molécula de ligação de antígeno capaz de evitar reações adversas que possam ser causadas pelo encadeamento cruzado de células t a outros imunócitos, e fornece uma molécula de ligação de antígeno adequada como remédio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013232803 | 2013-11-11 | ||
PCT/JP2014/079785 WO2015068847A1 (ja) | 2013-11-11 | 2014-11-11 | 改変された抗体可変領域を含む抗原結合分子 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016010025A2 true BR112016010025A2 (pt) | 2017-12-05 |
Family
ID=53041619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016010025A BR112016010025A2 (pt) | 2013-11-11 | 2014-11-11 | molécula de ligação de antígeno contendo região variável de anticorpo modificado |
Country Status (12)
Country | Link |
---|---|
US (3) | US20160280787A1 (pt) |
EP (1) | EP3070168A4 (pt) |
JP (3) | JPWO2015068847A1 (pt) |
KR (2) | KR20230104764A (pt) |
CN (3) | CN105940107B (pt) |
AU (1) | AU2014347565B2 (pt) |
BR (1) | BR112016010025A2 (pt) |
CA (1) | CA2929044A1 (pt) |
EA (1) | EA201600354A1 (pt) |
MX (1) | MX2016005762A (pt) |
TW (2) | TWI712421B (pt) |
WO (1) | WO2015068847A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2862875B1 (en) | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
TWI712421B (zh) | 2013-11-11 | 2020-12-11 | 日商中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
EP3219724A4 (en) * | 2014-11-11 | 2018-09-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
WO2016182064A1 (ja) | 2015-05-13 | 2016-11-17 | 中外製薬株式会社 | 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法 |
BR112019012901A2 (pt) | 2016-12-22 | 2020-01-07 | Daiichi Sankyo Company, Limited | Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula |
WO2018156106A1 (en) * | 2017-02-22 | 2018-08-30 | Ding Enyu | An mrna cancer vaccine encoding human gm-csf fused to multiple tandem epitopes |
US20200109205A1 (en) * | 2017-03-31 | 2020-04-09 | The Regents Of The University Of California | Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
US20200399373A1 (en) * | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
WO2019161386A1 (en) * | 2018-02-19 | 2019-08-22 | New York University | Alpha-synuclein single domain antibodies |
SG11202102882YA (en) * | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule comprising altered antibody variable region |
AU2019347412A1 (en) * | 2018-09-28 | 2021-05-27 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously |
JP2022538374A (ja) * | 2019-06-28 | 2022-09-02 | 中外製薬株式会社 | Pdgf-bおよびpdgf-dに結合する抗原結合分子ならびにその使用 |
CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
US20230121511A1 (en) * | 2020-03-31 | 2023-04-20 | Chugai Seiyaku Kabushiki Kaisha | Method for producing multispecific antigen-binding molecules |
JP7085666B2 (ja) | 2020-03-31 | 2022-06-16 | 中外製薬株式会社 | Dll3標的多重特異性抗原結合分子およびその使用 |
EP4159765A1 (en) * | 2020-06-01 | 2023-04-05 | Mustbio Co., Ltd. | Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor |
WO2023081266A2 (en) * | 2021-11-03 | 2023-05-11 | University Of Pittsburgh – Of The Commonwealth System Of Higher Education | Molecules that bind to protogenin (prtg) polypeptides |
CN116178567A (zh) * | 2022-10-28 | 2023-05-30 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
EP0266032A1 (en) | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ATE185601T1 (de) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | Verfahren zur herstellung von spezifischen bindungspaargliedern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
WO1992019973A1 (en) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
WO1994018221A1 (en) * | 1993-02-02 | 1994-08-18 | The Scripps Research Institute | Methods for producing polypeptide binding sites |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
JP2002522029A (ja) | 1998-07-27 | 2002-07-23 | ジェネンテック・インコーポレーテッド | コートタンパク質の改変によるファージ提示における改良した形質転換効率 |
AU1219000A (en) | 1998-10-22 | 2000-05-08 | Regents Of The University Of California, The | Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
EP1293514B1 (en) | 2001-09-14 | 2006-11-29 | Affimed Therapeutics AG | Multimeric single chain tandem Fv-antibodies |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
EP2154157A3 (en) | 2004-01-12 | 2010-04-28 | Applied Molecular Evolution Inc. | FC region variants |
DE602005027309D1 (de) | 2004-01-16 | 2011-05-19 | Regeneron Pharma | Zur aktivierung von rezeptoren fähige fusionspolypeptide |
SI2471813T1 (sl) | 2004-07-15 | 2015-03-31 | Xencor, Inc. | Optimirane Fc variante |
EP1778726A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
SI1797127T1 (sl) | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modificirane fc-molekule |
JP2008518023A (ja) * | 2004-10-27 | 2008-05-29 | メディミューン,インコーポレーテッド | 同族抗原に対する親和性を改変することによる抗体特異性の調節 |
CN101123983A (zh) * | 2004-10-27 | 2008-02-13 | 米迪缪尼股份有限公司 | 特定修饰对相关抗原的亲和力来调节抗体的特异性 |
EP2325207B1 (en) | 2004-11-12 | 2017-03-15 | Xencor, Inc. | FC variants with altered binding to FCRN |
PL1772465T3 (pl) | 2005-01-05 | 2009-08-31 | F Star Biotechnologische Forschungs Und Entw M B H | Syntetyczne domeny immunoglobulinowe o właściwościach wiążących modyfikowane w regionach cząsteczki różnych od regionów determinujących komplementarność |
CA2596248A1 (en) | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Method to identify polypeptide toll-like receptor (tlr) ligands |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
EP1870458B1 (en) | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2 STRUCTURAL ISOMERS |
CN101262885B (zh) * | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
CA2611726C (en) | 2005-06-10 | 2017-07-11 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(fv)2 |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
DK2009101T3 (en) | 2006-03-31 | 2018-01-15 | Chugai Pharmaceutical Co Ltd | Antibody modification method for purification of a bispecific antibody |
WO2007121354A2 (en) | 2006-04-14 | 2007-10-25 | Trubion Pharmaceuticals Inc. | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions |
EP2522678A1 (en) | 2006-05-15 | 2012-11-14 | Sea Lane Biotechnologies, LLC | Neutralizing antibodies to influenza viruses |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
WO2008119565A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific binding domain |
WO2009011941A2 (en) | 2007-04-04 | 2009-01-22 | The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services | Monoclonal antibodies against dengue and other viruses with deletion in fc region |
SG10201605394SA (en) | 2007-09-26 | 2016-08-30 | Chugai Pharmaceutical Co Ltd | Modified Antibody Constant Region |
WO2009086320A1 (en) | 2007-12-26 | 2009-07-09 | Xencor, Inc | Fc variants with altered binding to fcrn |
KR20100116179A (ko) | 2008-01-11 | 2010-10-29 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | 항-cldn6 항체 |
WO2009099961A2 (en) | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
NZ623716A (en) | 2008-04-11 | 2016-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
EP2283358B1 (en) | 2008-04-29 | 2015-04-22 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
EP2324061B1 (en) * | 2008-09-03 | 2017-04-12 | F. Hoffmann-La Roche AG | Multispecific antibodies |
CN105601745B (zh) | 2008-09-26 | 2020-09-08 | Ucb医药有限公司 | 生物产品 |
ES2732191T3 (es) | 2008-12-19 | 2019-11-21 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
RU2675997C2 (ru) | 2009-11-11 | 2018-12-25 | Ганимед Фармасьютикалз Аг | Антитела, специфичные к клаудину 6 (cldn6) |
DK2530091T3 (en) | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
KR102152109B1 (ko) | 2010-04-20 | 2020-09-07 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
RU2624027C2 (ru) | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Получение гетеромультимерных белков |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
CN103328514B (zh) | 2010-11-09 | 2015-12-02 | 阿尔蒂单抗治疗公司 | 用于抗原结合的蛋白复合物及其使用方法 |
LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
US20140080153A1 (en) | 2011-01-07 | 2014-03-20 | Chugai Seiyaku Kabushiki Kaisha | Method for improving physical properties of antibody |
EP2663334A4 (en) | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
MX348071B (es) | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
NZ706004A (en) | 2011-05-13 | 2016-12-23 | Ganymed Pharmaceuticals Ag | Antibodies for treatment of cancer expressing claudin 6 |
CA2836857C (en) * | 2011-05-21 | 2019-12-03 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
TWI687439B (zh) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | 異源二聚化多胜肽 |
US9238689B2 (en) | 2011-07-15 | 2016-01-19 | Morpho Sys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) |
MY169358A (en) | 2011-08-23 | 2019-03-26 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
US9868774B2 (en) * | 2011-10-20 | 2018-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
CN109897103B (zh) | 2011-11-04 | 2024-05-17 | 酵活英属哥伦比亚有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
MX2014010074A (es) | 2012-02-24 | 2014-09-12 | Stem Centrx Inc | Moduladores de ligando de tipo delta 3 (dll3) y metodos de uso. |
TWI797443B (zh) | 2012-05-30 | 2023-04-01 | 日商中外製藥股份有限公司 | 抗原結合分子之篩選或製造方法 |
EP2862875B1 (en) * | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
MX369276B (es) | 2012-11-13 | 2019-11-04 | Biontech Ag | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. |
WO2014075697A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
SI2968520T1 (sl) | 2013-03-14 | 2022-01-31 | Macrogenics, Inc. | Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor |
AU2014346792A1 (en) | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
TWI712421B (zh) | 2013-11-11 | 2020-12-11 | 日商中外製藥股份有限公司 | 含改變的抗體可變區之抗原結合分子 |
US20170274072A1 (en) | 2014-03-26 | 2017-09-28 | Tohoku University | Bispecific antibody targeting human epidermal growth factor receptor |
PL3130606T3 (pl) | 2014-04-07 | 2022-02-07 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciała dwuswoiste aktywujące układ odpornościowy |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3219724A4 (en) | 2014-11-11 | 2018-09-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
EP3732195A4 (en) | 2017-12-28 | 2022-02-09 | Chugai Seiyaku Kabushiki Kaisha | CYTOTOXICITY-INDUCING THERAPEUTIC |
JP2021510064A (ja) | 2018-01-05 | 2021-04-15 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
SG11202102882YA (en) | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule comprising altered antibody variable region |
AU2019347412A1 (en) | 2018-09-28 | 2021-05-27 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules capable of binding CD3 and CD137 but not simultaneously |
TWI770917B (zh) | 2020-03-31 | 2022-07-11 | 日商中外製藥股份有限公司 | 密連蛋白6靶向多特異性抗原結合分子及其用途 |
JP2021175391A (ja) | 2020-03-31 | 2021-11-04 | 中外製薬株式会社 | 免疫活性化多重特異性抗原結合分子およびその使用 |
JP7085666B2 (ja) | 2020-03-31 | 2022-06-16 | 中外製薬株式会社 | Dll3標的多重特異性抗原結合分子およびその使用 |
US20230121511A1 (en) | 2020-03-31 | 2023-04-20 | Chugai Seiyaku Kabushiki Kaisha | Method for producing multispecific antigen-binding molecules |
-
2014
- 2014-11-11 TW TW108101781A patent/TWI712421B/zh active
- 2014-11-11 CN CN201480072799.3A patent/CN105940107B/zh active Active
- 2014-11-11 WO PCT/JP2014/079785 patent/WO2015068847A1/ja active Application Filing
- 2014-11-11 MX MX2016005762A patent/MX2016005762A/es unknown
- 2014-11-11 CN CN202110577978.4A patent/CN113307873A/zh active Pending
- 2014-11-11 KR KR1020237022012A patent/KR20230104764A/ko not_active Application Discontinuation
- 2014-11-11 CA CA2929044A patent/CA2929044A1/en active Pending
- 2014-11-11 US US15/035,098 patent/US20160280787A1/en not_active Abandoned
- 2014-11-11 JP JP2015546719A patent/JPWO2015068847A1/ja not_active Withdrawn
- 2014-11-11 TW TW103138989A patent/TWI652279B/zh active
- 2014-11-11 KR KR1020167015015A patent/KR102551410B1/ko active IP Right Grant
- 2014-11-11 BR BR112016010025A patent/BR112016010025A2/pt active Search and Examination
- 2014-11-11 CN CN202110579555.6A patent/CN113278076A/zh active Pending
- 2014-11-11 EA EA201600354A patent/EA201600354A1/ru unknown
- 2014-11-11 EP EP14859814.7A patent/EP3070168A4/en active Pending
- 2014-11-11 AU AU2014347565A patent/AU2014347565B2/en active Active
-
2019
- 2019-12-05 US US16/704,464 patent/US11739149B2/en active Active
-
2020
- 2020-08-25 JP JP2020141381A patent/JP7512129B2/ja active Active
-
2022
- 2022-10-20 JP JP2022168321A patent/JP2022191448A/ja active Pending
-
2023
- 2023-06-30 US US18/345,750 patent/US20240026000A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2014347565B2 (en) | 2020-08-13 |
US20200332001A1 (en) | 2020-10-22 |
MX2016005762A (es) | 2016-08-19 |
KR102551410B1 (ko) | 2023-07-04 |
CA2929044A1 (en) | 2015-05-14 |
TW201605900A (zh) | 2016-02-16 |
CN105940107B (zh) | 2021-06-15 |
TW201919701A (zh) | 2019-06-01 |
EP3070168A4 (en) | 2017-06-28 |
CN105940107A (zh) | 2016-09-14 |
TWI712421B (zh) | 2020-12-11 |
US20240026000A1 (en) | 2024-01-25 |
US20160280787A1 (en) | 2016-09-29 |
JPWO2015068847A1 (ja) | 2017-03-09 |
KR20160083094A (ko) | 2016-07-11 |
JP7512129B2 (ja) | 2024-07-08 |
CN113278076A (zh) | 2021-08-20 |
KR20230104764A (ko) | 2023-07-10 |
TWI652279B (zh) | 2019-03-01 |
EA201600354A1 (ru) | 2016-12-30 |
US11739149B2 (en) | 2023-08-29 |
EP3070168A1 (en) | 2016-09-21 |
JP2022191448A (ja) | 2022-12-27 |
JP2020196741A (ja) | 2020-12-10 |
WO2015068847A1 (ja) | 2015-05-14 |
CN113307873A (zh) | 2021-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016010025A2 (pt) | molécula de ligação de antígeno contendo região variável de anticorpo modificado | |
BR112016030908A2 (pt) | moléculas com especificidade para cd45 e cd79 | |
BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
BR112014025830A8 (pt) | Polipeptídeos de ligação ao cd3 | |
BR112017011235A2 (pt) | anticorpos anti-c5 e métodos de uso | |
BR112017026330A2 (pt) | molécula de ligação de lag-3 capaz de ligação tanto o lag-3 humano quanto ao lag-3 de macaco cynomolgus | |
EA201591376A1 (ru) | Конструкции антител к cdh19 и cd3 | |
EP3816179A3 (en) | Fc region variant comprising a modified fcrn-binding domain | |
BR112014007382A2 (pt) | anticorpos anti-erbb3 e seus usos | |
BR112018000475A2 (pt) | construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3 | |
MX351349B (es) | Proteinas de union a antigeno. | |
BR112012028764A2 (pt) | anticor-pos antifgfr2 | |
BR112018001374A2 (pt) | construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3 | |
PH12015501672A1 (en) | Binding molecules for bcma and cd3 | |
BR112018068678A2 (pt) | anticorpos anti-mica | |
BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
AR094896A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
BR112016011401A2 (pt) | moduladores de aplnr e utilizações dos mesmos | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
EA201891709A1 (ru) | Антигенсвязывающие белки, связывающие pd-l1 | |
EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
BR112018009067A8 (pt) | anticorpos anti-c5 e métodos de uso | |
BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
BR112018067951A2 (pt) | moléculas que se ligam a ilt7 e métodos de uso destas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |